Hyatt Regency Bethesda Hotel
Bethesda, Md.

Proteomics has the potential to discover, verify, and accurately measure novel biomarkers for more informed drug development and clinical decisions in neuroscience, but how close are we to these goals? This day-long workshop, “Proteomics in Neuroscience”, sponsored by the Biomarkers Consortium Neuroscience Steering Committee, provided a forum for industry, government, and academia to examine the biomarker development pathway, from discovery to validated assays, using mass spectrometry-based proteomic approaches.  

Presentations and panel discussions highlighted:

• The current state of the art in unbiased proteomic profiling of plasma and cerebrospinal fluid proteomics profiling
• Multiplexed approaches for targeted verification of candidate biomarkers
• The criteria that need to be met for use of multiplexed mass spectrometry measurements for FDA registration of
  biomarkers and diagnostics

Speakers presented technological approaches and success stories from oncology and cardiovascular medicine in addition to neuroscience. These presentations addressed whether proteomics is ready for broader adoption in neuroscience, its limitations, and lessons learned for its successful application.

Confirmed speakers and participants in this meeting represented all sectors of biomedical science an the current stakeholders of The Biomarkers Consortium representing academia, non-profit, governments and industry included, The Foundation for NIH, National Institutes of Health, Food and Drug Administration, and pharmaceutical companies working in this space.

Howard Schulman, Ph.D.
Workshop Chair

Judy Siuciak, Ph.D.
Scientific Program Manager, Neuroscience Steering Committee
The Biomarkers Consortium, Foundation for NIH